CTI BioPharma (CTIC) PT Raised to $12 at Brookline Capital Markets Following FDA Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Increasing unusual option volume: MULN EQNR APLS WEAT CTIC
March 1, 2022 9:53 AM ESTIncreasing unusual option volume: MULN EQNR APLS WEAT CTIC
... MorePre-Open Stock Movers 03/01: (CTIC) (TGT) (DDD) Higher; (GDRX) (VRM) (AMBA) Lower (more...)
March 1, 2022 9:27 AM ESTPre-Open Stock Movers:
CTI BioPharma Corp. (Nasdaq: CTIC) 54% HIGHER; announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 Ã-109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the... More
CTI BioPharma (CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO
March 1, 2022 7:17 AM ESTCTI BioPharma (NASDAQ: CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO
... MoreStifel Reiterates Buy Rating on CTI BioPharma (CTIC), Expects Stock to Trade Up Substantially on Vonjo Approval
March 1, 2022 6:41 AM ESTStifel analyst Benjamin Burnett reiterated a Buy rating on CTI BioPharma (NASDAQ: CTIC), following approval of the company's Vonjo drug.
The analyst quotes: "We reiterate our Buy rating on CTIC following the approval of Vonjo (pacritinib) for the treatment of myelofibrosis patients with severe thrombocytopenia.... More
CTI BioPharma (CTIC) Granted FDA Accelerated Approval of VONJO
March 1, 2022 6:01 AM ESTCTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the first approved therapy that specifically addresses the needs of patients with cytopenic myelofibrosis.
"Today's approval of VONJO establishes a new standard of... More
